One of the most widely used esthetic restorations in dentistry is composite. The widespread application of composites can be related to advancements in biomaterials. However, due to various factors, composites are commonly associated with dental sensitivity. Hence, the present study evaluates and compares the effectiveness of three desensitizing agents in reducing post-treatment sensitivity for Class I composite restoration. Eighty subjects with Class I cavities were selected according to the inclusion criteria, and a randomized, double-blind, controlled clinical trial was carried out. Twenty patients were randomly assigned to four groups: Group C (Control group), Group GL (Gluma group), Group SF (Shield Force Plus group), and Group TC (Telio CS group). The desensitizers were applied after Class 1 cavity preparation and acid etching in all the groups, except the Control group, and thereafter, composite restoration was completed in a conventional manner. Questionnaires were provided to all the participants to record the post-operative pain/sensitivity level according to the visual analogue scale (VAS) on intake of cold drinks, intake of hot drinks, and intake of sugar for different periods of time. Significant variation was observed between the three desensitizers for all three stimuli. However, no significant variations were seen with the various age groups and between the maxillary and the mandibular teeth at the different time periods. Group GL performed better than Group SF and Group TC. It can be proposed that the application of the desensitizers reduced the post-restorative sensitivity in the composite restorations and improved acceptance.

Background: dental pulp-derived stem cells are easy to access and collect and are an excellent source of stem cells for regenerative therapy. These cells can interact with many biomolecules and scaffolds and can pass on the instructive signals to the sites of regeneration where they are used. In this regard cordycepin, a potential biomolecule derived from medicinal mushrooms with a spectrum of bioactive properties such as antioxidant, anti-inflammatory, and anticancer has not yet been tested for its effect on human dental pulp stem cells. Objective: the objective of the present study was to assess the in vitro adipogenic and osteogenic differentiation potential of human dental pulp stem cells with or without induction after administration of cordycepin. Materials and methods: human dental pulp stem cells DPSCs were isolated from a healthy permanent tooth extracted for orthodontic purposes after obtaining informed consent. Flow cytometry technique was used to assess the surface markers of these cells such as CD73, CD90, and CD105, CD34, CD45, and HLA-DR. Further, an MTT assay was performed on the cells after subjecting them to various concentrations of cordycepin. Following this, the adipogenic and osteogenic potential of the dental pulp stem cells was assessed with or without induction under the influence/absence of 5 µM of cordycepin. The results obtained were statistically analyzed and documented. Results: it was found that the dental pulp stem cells showed strong positive expression for CD73, CD90, and CD105 and faint expression of CD34, CD45, and HLA-DR. MTT assay revealed that 5 µM was the optimum concentration of cordycepin for all the assays. Concerning adipogenesis experiments, there was a statistically significant lowering of all the 4 adipogenesis-related genes PPARγ, FABP4, LPL, and C/EBPα following cordycepin treatment in the presence of induction compared to the only induction group and untreated control cells (p < 0.05). In connection with osteogenesis, was found that there was a statistically significant increase in the expression of RUNX2, COL1A1, OSX and OCN genes along with the increase in alkaline phosphatase and alizarin red staining in the DPSC treated with cordycepin along with the presence of induction and simultaneous addition of PDTC compared to the control untreated cells and cells treated with induction and simultaneous addition of PDTC (p < 0.05). Conclusion: cordycepin can be exploited for its osteopromotive properties and can be used as a bioactive molecule alongside the administration of dental pulp stem cells in the area of regenerative biology and medicine.